Keystone Clinical Studies — research payments reported

By program year

4 rows

Year	Kind	Amount	Payments
2025	Research	$71,378	2
2021	Research	$156,229	17
2020	Research	$156,893	16
2019	Research	$16,254	2

Breakdown

Who paid Research payments · program years 2019–2025

AbbVie, Inc. $188,481 24 payments
Avanir Pharmaceuticals, Inc. $82,966 8 payments
E.R. Squibb & Sons, L.L.C. $71,378 2 payments
Merck Sharp & Dohme Corporation $57,929 3 payments

Studies the money was for Research payments · program years 2019–2025

M15-566 $95,948 13 payments
18-Avp-786-207 $80,466 7 payments
A Phase 2 Multiple Dose, Multicenter, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of ABBV-8E12 in Subjects with Early Alzheimers Disease $73,106 5 payments
A Phase 3, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Study to Evaluate the Efficacy and Safety of KarXT + KarX-EC for the Treatment of Cognitive Impairment Associated with Mild-to-Moderate Alzheimers Disease (MINDSET 2) $68,485 1 payment
A Phase 2a, Randomized, Placebo-Controlled Clinical Study to Evaluate the Efficacy and Safety of MK-1942 Added to Stable Antidepressant Therapy in Participants With Treatment-Resistant Depression $57,929 3 payments
An Extension Study of ABBV-8E12 in Early Alzheimers Disease $19,428 6 payments
A Phase 3, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Study to Evaluate the Efficacy and Safety of KarXT + KarX-EC for the Treatment of Cognitive Impairment Associated with Mild-to-Moderate Alzheimers Disease (MINDSET 2) $2,893 1 payment
17-Avp-786-305 $2,500 1 payment

What you are looking at

A noncovered recipient is an organisation paid for research that is neither an individual clinician nor a teaching hospital — typically a contract research organisation, a foundation or a trial site network. They receive 81% of all reported research money, which is why they appear here at all.